LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

LLY

1,060.07

+2.14%↑

JNJ

234.4

+2.13%↑

ABBV

217.8

+1.79%↑

UNH

389.25

+1.03%↑

AZN

186.95

-0.56%↓

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Deschisă

SectorSănătate

20.65 0.19

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

20.55

Maxim

21.32

Indicatori cheie
By Trading Economics
Venit	-29M -11M
Vânzări	-24M 105M
EPS	-0.09
Marjă de profit	-10.717
Angajați	354
EBITDA	-31M -8.5M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+69.17% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-433M 2.5B
Deschiderea anterioară	20.46
Închiderea anterioară	20.65

Sentimentul știrilor

By Acuity

50%

148 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

12.42 / 14.93 Suport & Rezistență

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 mai 2026, 22:48 UTC

Achiziții, Fuziuni, Preluări

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mai 2026, 16:49 UTC

Câștiguri

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mai 2026, 16:26 UTC

Principalele dinamici ale pieței

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mai 2026, 22:33 UTC

Achiziții, Fuziuni, Preluări

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mai 2026, 21:53 UTC

Câștiguri

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mai 2026, 21:02 UTC

Câștiguri

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mai 2026, 20:55 UTC

Câștiguri

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mai 2026, 20:30 UTC

Acțiuni populare

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mai 2026, 20:20 UTC

Câștiguri

Webull 1Q Adj EPS 3c >BULL

21 mai 2026, 20:20 UTC

Câștiguri

Webull 1Q Rev $159.9M >BULL

21 mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mai 2026, 20:18 UTC

Câștiguri

Webull 1Q Loss/Shr 4c

21 mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mai 2026, 18:58 UTC

Câștiguri

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mai 2026, 17:01 UTC

Câștiguri

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mai 2026, 16:20 UTC

Market Talk

Câștiguri

Stellantis Targets Distant but Constructive -- Market Talk

21 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

69.17% sus

Prognoză pe 12 luni

Medie 34.63 USD 69.17%

Maxim 36 USD

Minim 33 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

12.42 / 14.93Suport & Rezistență

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

148 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.